Business Context and Reporting Period
Company: Amphastar Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 7, 2018
Reporting Period: Event-based report for November 7, 2018.
Business Context: The registrant is an emerging growth company incorporated in Delaware. The filing reports a significant regulatory milestone regarding a new drug application.
Key Financial Metrics
This Form 8-K is an event-driven report and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event reported is the approval by the U.S. Food and Drug Administration (FDA) of the Company's new drug application for Primatene® Mist (epinephrine inhalation aerosol bronchodilator suspension). This approval was announced via a press release issued on November 7, 2018.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release (Exhibit 99.1) detailing the FDA approval. No specific financial guidance, forward-looking projections, or management outlook regarding future earnings is included in the text of this report.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard regulatory context of the drug approval.
Key Facts for Investor Verification
- Verify the commercial launch timeline and expected revenue contribution of Primatene® Mist following FDA approval.
- Review the full text of the press release filed as Exhibit 99.1 for details on the approval scope and market strategy.
- Confirm the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Check subsequent filings for any financial impact analysis related to this regulatory approval.